Millennium Pharmacon International (IDX:SDPC) - Share price, News & Analysis

SDPC fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	4/6
Financial Health	3/6
Dividends	1/6

SDPC Stock Overview

PT Millennium Pharmacon International Tbk engages in the distribution and trading of prescription and non-prescription medicines, dietary supplements, and medical devices in Indonesia.

Rewards

PE ratio (17.2x) is below the ID market (18.9x)

Earnings grew by 241.3% over the past year

Risk Analysis

Earnings have declined by 21.5% per year over past 5 years

Interest payments are not well covered by earnings

Does not have a meaningful market cap (IDR164B)

Millennium Pharmacon International Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Millennium Pharmacon International
Historical stock prices
Current Share Price	Rp129.00
52 Week High	Rp214.00
52 Week Low	Rp107.00
Beta	0.51
1 Month Change	7.50%
3 Month Change	-3.01%
1 Year Change	0%
3 Year Change	22.86%
5 Year Change	5.74%
Change since IPO	637.14%

Shareholder Returns

	SDPC	ID Healthcare	ID Market
7D	0.8%	3.4%	-1.0%
1Y	0%	16.8%	18.2%

Return vs Industry: SDPC underperformed the ID Healthcare industry which returned 16.8% over the past year.

Return vs Market: SDPC underperformed the ID Market which returned 18.2% over the past year.

Price Volatility

Is SDPC's price volatile compared to industry and market?
SDPC volatility
SDPC Average Weekly Movement	6.3%
Healthcare Industry Average Movement	5.5%
Market Average Movement	6.3%
10% most volatile stocks in ID Market	12.2%
10% least volatile stocks in ID Market	3.0%

Stable Share Price: SDPC is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: SDPC's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1952	1,075	Ahmad Bin Abu Bakar	https://www.mpi-indonesia.co.id

PT Millennium Pharmacon International Tbk engages in the distribution and trading of prescription and non-prescription medicines, dietary supplements, and medical devices in Indonesia. The company distributes its products through drug stores, pharmacies, hospitals, supermarkets, and retail shops. As of December 31, 2021, it operated 33 branch offices in Java, Bali, Sumatera, Kalimantan, and Sulawesi Islands.

Millennium Pharmacon International Fundamentals Summary

How do Millennium Pharmacon International's earnings and revenue compare to its market cap?
SDPC fundamental statistics
Market Cap	Rp164.35b
Earnings (TTM)	Rp9.57b
Revenue (TTM)	Rp2.99t

17.2x

P/E Ratio

0.1x

P/S Ratio

Is SDPC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SDPC income statement (TTM)
Revenue	Rp2.99t
Cost of Revenue	Rp2.75t
Gross Profit	Rp237.04b
Other Expenses	Rp227.47b
Earnings	Rp9.57b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	7.51
Gross Margin	7.93%
Net Profit Margin	0.32%
Debt/Equity Ratio	200.4%

How did SDPC perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

7%

Payout Ratio

Valuation

Is Millennium Pharmacon International undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

17.17x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: SDPC (IDR129) is trading above our estimate of fair value (IDR5.21)

Significantly Below Fair Value: SDPC is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: SDPC is good value based on its PE Ratio (17.2x) compared to the ID Healthcare industry average (19.9x).

PE vs Market: SDPC is good value based on its PE Ratio (17.2x) compared to the ID market (18.9x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SDPC's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: SDPC is good value based on its PB Ratio (0.7x) compared to the ID Healthcare industry average (1.9x).

Future Growth

How is Millennium Pharmacon International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

16.7%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Millennium Pharmacon International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Millennium Pharmacon International performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-21.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SDPC has high quality earnings.

Growing Profit Margin: SDPC's current net profit margins (0.3%) are higher than last year (0.1%).

Past Earnings Growth Analysis

Earnings Trend: SDPC's earnings have declined by 21.5% per year over the past 5 years.

Accelerating Growth: SDPC's earnings growth over the past year (241.3%) exceeds its 5-year average (-21.5% per year).

Earnings vs Industry: SDPC earnings growth over the past year (241.3%) exceeded the Healthcare industry 121.6%.

Return on Equity

High ROE: SDPC's Return on Equity (4%) is considered low.

Financial Health

How is Millennium Pharmacon International's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: SDPC's short term assets (IDR1,070.3B) exceed its short term liabilities (IDR942.6B).

Long Term Liabilities: SDPC's short term assets (IDR1,070.3B) exceed its long term liabilities (IDR26.8B).

Debt to Equity History and Analysis

Debt Level: SDPC's net debt to equity ratio (180.4%) is considered high.

Reducing Debt: SDPC's debt to equity ratio has reduced from 206.5% to 200.4% over the past 5 years.

Debt Coverage: SDPC's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: SDPC's interest payments on its debt are not well covered by EBIT (1.4x coverage).

Balance Sheet

Dividend

What is Millennium Pharmacon International current dividend yield, its reliability and sustainability?

Dividend Score

1/6

Dividend Score 1/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

0.39%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: SDPC's dividend (0.39%) isn’t notable compared to the bottom 25% of dividend payers in the ID market (1.12%).

High Dividend: SDPC's dividend (0.39%) is low compared to the top 25% of dividend payers in the ID market (4.1%).

Stability and Growth of Payments

Stable Dividend: SDPC has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: SDPC has only been paying a dividend for 6 years, and since then payments have fallen.

Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (6.7%), SDPC's dividend payments are thoroughly covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: SDPC is paying a dividend but the company has no free cash flows.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure

CEO

Ahmad Bin Abu Bakar (52 yo)

1.75yrs

Tenure

Mr. Ahmad Bin Abu Bakar serves as President Director at PT Millennium Pharmacon International Tbk since August 2020. He has been a Director at PT Millennium Pharmacon International TBK. since September 29,...

Leadership Team

Experienced Management: SDPC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Experienced Board: SDPC's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/19 00:00
End of Day Share Price	2022/05/19 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31